The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports
- PMID: 34002816
- DOI: 10.26355/eurrev_202105_25823
The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports
Abstract
Objective: Adenomyosis is the consequence of the myometrial invasion by endometrial glands and stroma. Transvaginal ultrasonography plays a decisive role in the diagnosis and monitoring of this pathology. Our study aims to evaluate the efficacy of LNG-IUS (Levonorgestrel Releasing Intrauterine System) as medical therapy. We analyzed both clinical symptoms and ultrasonographic aspects of menometrorrhagia and dysmenorrhea in patients with adenomyosis and the control group.
Patients and methods: A prospective cohort study was carried out on 28 patients suffering from symptomatic adenomyosis treated with LNG-IUS. Adenomyosis was diagnosed through transvaginal ultrasonography by an expert sonographer. A control group of 27 symptomatic patients (menorrhagia and dysmenorrhea) without a transvaginal ultrasonographic diagnosis of adenomyosis was treated in the same way. The two cohorts were compared to the efficacy of LNG-IUS on menorrhagia and dysmenorrhea. Patients are evaluated at the time of LNG-IUS insertion and six months after for: increased uterine volume, globulous uterine morphology, uterine symmetry, alterations in the junctional zone, heterogeneous myometrial texture, presence of myometrial cysts, hyperechogenic lines crossing the myometrium, adenomyomas, menstrual blood loss and dysmenorrhea.
Results: After six months, the uterine volume decreased significantly in both cohorts (p=0.005; p=0.005). Furthermore, uterine symmetry, visibility of the junctional zone, heterogeneity of myometrial texture, presence of myometrial cysts, hyperechogenic lines and adenomyomas improved in patients affected by adenomyosis (p>0.001; p>0.001; p>0.001; p=0.014; p=0.025; p=0.014). The blood loss decreased significantly in both the cohorts (p<0.001) and particularly in adenomyotic patients. Pain relief was observed in all the patients (p<0.001).
Conclusions: LNG-IUS can be considered an effective treatment for managing symptoms and improving uterine morphology.
Similar articles
-
Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis.Taiwan J Obstet Gynecol. 2015 Aug;54(4):412-5. doi: 10.1016/j.tjog.2014.05.009. Taiwan J Obstet Gynecol. 2015. PMID: 26384061
-
Levonorgestrel-Releasing Intrauterine System Improves Menorrhagia-Related Quality of Life in Patients with Symptomatic Adenomyosis.Reprod Sci. 2023 Mar;30(3):966-973. doi: 10.1007/s43032-022-01077-9. Epub 2022 Sep 7. Reprod Sci. 2023. PMID: 36071343
-
[A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia].Zhonghua Fu Chan Ke Za Zhi. 2016 Jun 25;51(6):424-30. doi: 10.3760/cma.j.issn.0529-567X.2016.06.005. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27356477 Chinese.
-
The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis.Reprod Biol Endocrinol. 2025 Feb 13;23(1):23. doi: 10.1186/s12958-025-01349-4. Reprod Biol Endocrinol. 2025. PMID: 39948612 Free PMC article.
-
The role of levonorgestrel intra-uterine system in the management of adenomyosis: A systematic review and meta-analysis of prospective studies.Acta Obstet Gynecol Scand. 2020 May;99(5):571-581. doi: 10.1111/aogs.13798. Epub 2020 Jan 24. Acta Obstet Gynecol Scand. 2020. PMID: 31889294
Cited by
-
In-office hysteroscopic removal of retained or fragmented intrauterine device without anesthesia: a cross-sectional analysis of an international survey.Updates Surg. 2022 Jun;74(3):1079-1085. doi: 10.1007/s13304-022-01246-0. Epub 2022 Feb 5. Updates Surg. 2022. PMID: 35122582 Free PMC article.
-
Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis.Open Med (Wars). 2024 Mar 21;19(1):20240914. doi: 10.1515/med-2024-0914. eCollection 2024. Open Med (Wars). 2024. PMID: 38584829 Free PMC article.
-
Quality of Life of Japanese Dysmenorrhea/Heavy Menstrual Bleeding Patients Treated with Levonorgestrel Intrauterine Delivery System in a Real-World Setting.Adv Ther. 2022 Aug;39(8):3616-3634. doi: 10.1007/s12325-022-02205-2. Epub 2022 Jun 16. Adv Ther. 2022. PMID: 35705788 Free PMC article.
-
Women's experience, satisfaction, and continuation with the levonogestrel-containing intrauterine system: A cross-sectional study.Medicine (Baltimore). 2024 Dec 27;103(52):e41063. doi: 10.1097/MD.0000000000041063. Medicine (Baltimore). 2024. PMID: 39969376 Free PMC article.
-
Efficacy of hysteroscopic levonorgestrel‑releasing intrauterine device fixation in the treatment of adenomyosis: A cohort study.Biomed Rep. 2024 Jun 4;21(1):109. doi: 10.3892/br.2024.1797. eCollection 2024 Jul. Biomed Rep. 2024. PMID: 38868528 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical